David J. Mazzo, PhD
President, Chief Executive Officer and Director
Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
Senior Vice President and Chief Financial Officer
Prior to joining Caladrius, from 1996 to 2010, Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. (“OSI”), a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva®, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010.
Mr. Talamo received a BBA in accounting from Hofstra University in 1991, and an MBA in finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.
Douglas W. Losordo, MD, FACC, FAHA
Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
Dr. Losordo has engaged in career-long efforts to develop novel therapeutics and as a scientist he obtained over $35 million in National Institutes of Health funding, for discovering and developing new therapeutic concepts in the laboratory, providing the basis for clinical studies. He has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases, including therapies now in Phase 3 testing. He is a highly sought after speaker, having given over 200 international lectures. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association and serves on the editorial boards of a number of scientific journals. Since 2012, he has served on the Scientific Advisory Board of The Stem For Life Foundation, a public charity devoted to accelerating development of cell therapies.
Todd Girolamo, JD
General Counsel and Corporate Secretary
Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel, and he concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to over a decade of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Company and Summer Street Research Partners.
Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.
Vice President, Information Technology
Greg Berkin joined Caladrius in January 2015. Since that time, Greg has been responsible for transforming external IT support into an internal team working as a highly efficient operating unit across all five Caladrius and PCT sites. He also manages all groups within IT: Networking, PC, Applications, Business Solutions, and Telecom.
Before joining Caladrius, Greg held director and management roles in IT at companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.
Greg has more than 20 years in the technical profession with 15 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, and cybersecurity.
John D Menditto
Executive Director, Investor Relations and Corporate Communications
Mr. Menditto came to Caladrius with over 20 years of experience and specialization, particularly, in the areas of financial modeling, Regulation FD, corporate governance, investor targeting and capital raising. He has held senior roles at several healthcare and life science companies including Novartis Corporation, Medco Health Solutions and Argos Therapeutics. John has also spent a number of years as a senior communications consultant with The Imagination Group, Makovsky & Co. and MWWPR.
John is a former IR Magazine and PRSA/Big Apple award winner for his work in investor and corporate communications. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.